TROPION-Lung01, evaluating AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan versus chemotherapy, previously met the dual primary endpoint of progression-free survival in the overall trial population

TROPION-Lung01评估了阿斯利康和第一三共的达托帕单抗与化疗的比较，之前在整个试验人群中达到了无进展生存的双重主要终点

Presidential Symposium for NeoCOAST-2 demonstrates potential for datopotamab deruxtecan plus Imfinzi and chemotherapy in neoadjuvant early-stage non-small cell lung cancer

NeoCOAST-2总统研讨会显示达托帕单抗-德鲁替康联合Imfinzi和化疗治疗新辅助早期非小细胞肺癌的潜力

Detailed results from the TROPION-Lung01 Phase III trial showed a clinically meaningful trend toward improving overall survival (OS) with datopotamab deruxtecan (Dato-DXd) compared to docetaxel, the current standard of care chemotherapy, in adult patients with locally advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) treated with at least one prior line of therapy..

TROPION-Lung01 III期临床试验的详细结果显示，与多西紫杉醇（目前的标准化疗方案）相比，达托单抗-德鲁替康（Dato-DXd）治疗成人局部晚期或转移性非鳞状非小细胞肺癌（NSCLC）患者的总生存期（OS）有临床意义的趋势，至少有一种先前的治疗方案。。

These results will be presented today during an oral presentation (OA08.03) at the IASLC 2024 World Conference on Lung Cancer (WCLC) hosted by the International Association for the Study of Lung Cancer and simultaneously published in the Journal of Clinical Oncology.

这些结果将于今天在国际肺癌研究协会主办的IASLC 2024年世界肺癌会议（WCLC）上进行口头报告（OA08.03），并同时发表在《临床肿瘤学杂志》上。

Datopotamab deruxtecan is a specifically engineered TROP2-directed DXd antibody drug conjugate discovered by Daiichi Sankyo and being jointly developed by AstraZeneca and Daiichi Sankyo.

Datopotamab deruxtecan是由Daiichi Sankyo发现并由AstraZeneca和Daiichi Sankyo联合开发的特异性工程TROP2定向DXd抗体-药物偶联物。

In the overall trial population, OS results numerically favoured datopotamab deruxtecan compared to docetaxel (12.9 versus 11.8 months) but did not reach statistical significance (hazard ratio [HR] 0.94; 95% confidence interval [CI] 0.78-1.14; p=0.530). In the prespecified subgroup of patients with nonsquamous NSCLC, datopotamab deruxtecan showed a 2.3-month improvement in OS compared to docetaxel (14.6 versus 12.3 months; HR 0.84; 95% CI 0.68-1.05).

在总体试验人群中，与多西紫杉醇相比，OS结果在数值上有利于达托单抗-德鲁替康（12.9比11.8个月），但未达到统计学显着性（风险比[HR]0.94；95%置信区间[CI]0.78-1.14；p=0.530）。在预先指定的非鳞状细胞癌患者亚组中，与多西紫杉醇相比，达托单抗-德鲁替康的OS改善了2.3个月（14.6比12.3个月；HR 0.84；95%CI 0.68-1.05）。

In patients with nonsquamous NSCLC, OS improvement was observed regardless of the presence of actionable genomic alterations. In patients with squamous NSCLC, consistent with the previous analysis, datopotamab deruxtecan did not show an OS improvement..

在非鳞状细胞癌患者中，无论是否存在可行的基因组改变，均观察到OS改善。在鳞状非小细胞肺癌患者中，与之前的分析一致，达托帕单抗deruxtecan没有显示OS改善。。

Jacob Sands, MD, Dana-Farber Cancer Institute, Medical Oncology and investigator in the trial, said: “Despite many efforts to surpass docetaxel with novel approaches in previously treated advanced or metastatic non-small cell lung cancer, patients only survive for about one year. For datopotamab deruxtecan to show a statistically significant improvement in progression-free survival along with improved response rate, duration of response and an overall survival improvement numerically consistent with progression-free survival is clinically meaningful for patients with nonsquamous lung cancer.”.

Dana-Farber癌症研究所医学肿瘤学博士兼试验研究者Jacob Sands说：“尽管在先前治疗的晚期或转移性非小细胞肺癌中，许多人努力用新方法超越多西紫杉醇，但患者只能存活约一年。对于达托帕单抗-德鲁替康，无进展生存期的统计学显着改善以及改善的缓解率，缓解持续时间和总体生存期的改善在数值上与无进展生存期一致，对于非鳞癌患者具有临床意义。”。

Susan Galbraith, Executive Vice President, Oncology R&D, AstraZeneca, said: “TROPION-Lung01 showed a clinically meaningful trend towards improving the survival of patients with advanced or metastatic nonsquamous non-small cell lung cancer, building on the previously reported progression-free survival data.

阿斯利康肿瘤研发执行副总裁苏珊·加尔布雷斯（SusanGalbraith）表示：“TROPION-Lung01在改善晚期或转移性非鳞状非小细胞肺癌患者生存方面显示出临床上有意义的趋势，这是基于先前报道的无进展生存数据。

Together with the data we have presented for the potential TROP2-QCS biomarker and from NeoCOAST-2 in early-stage disease, these results underscore our confidence in the important role datopotamab deruxtecan can play across segments and settings of non-small cell lung cancer.”.

结合我们提供的潜在TROP2-QCS生物标志物和NeoCOAST-2在早期疾病中的数据，这些结果强调了我们对达托单抗deruxtecan在非小细胞肺癌的各个环节和环境中发挥重要作用的信心。”。

Ken Takeshita, MD, Global Head, R&D, Daiichi Sankyo, said: “For patients with nonsquamous non-small cell lung cancer, disease progression is common, making this patient population difficult to treat. The data from TROPION-Lung01 demonstrate the potential of datopotamab deruxtecan in this setting and support our comprehensive development programme where we are also evaluating this TROP2-directed antibody drug conjugate as part of combination strategies in earlier treatment settings of non-small cell lung cancer.” .

Daiichi Sankyo全球研发主管Ken Takeshita医学博士说：“对于非鳞状非小细胞肺癌患者，疾病进展很常见，使该患者群体难以治疗。来自TROPION-Lung01的数据证明了达托单抗deruxtecan在这种情况下的潜力，并支持我们的综合开发计划，我们还在评估这种TROP2导向的抗体-药物偶联物，作为非小细胞肺癌早期治疗环境中组合策略的一部分。”。

The safety profile of datopotamab deruxtecan in TROPION-Lung01 was consistent with the previous analysis including lower rates of dose reduction (20%, 30%) and discontinuation (8%, 12%) due to adverse events compared to docetaxel. The median treatment duration for datopotamab deruxtecan was 4.2 months versus 2.8 months for docetaxel.

与多西紫杉醇相比，达托单抗-德鲁替康在TROPION-Lung01中的安全性与之前的分析一致，包括由于不良事件导致的剂量减少率（20%，30%）和停药率（8%，12%）。。

Grade 3 or higher treatment-related adverse events (TRAEs) occurred in 26% and 42% of patients in the datopotamab deruxtecan and docetaxel arms, respectively. The most common Grade 3 or higher TRAEs were neutropenia (1%, 23%), leukopenia (0%, 13%), stomatitis (7%, 1%), anemia (4%, 4%), interstitial lung disease (ILD) (4%, 1 %) and asthenia (3%, 2%).

达托单抗-德鲁替康组和多西紫杉醇组分别有26%和42%的患者发生3级或更高的治疗相关不良事件（TRAEs）。最常见的3级或更高级别TRAE是中性粒细胞减少症（1%，23%），白细胞减少症（0%，13%），口腔炎（7%，1%），贫血（4%，4%），间质性肺病（ILD）（4%，1%）和虚弱（3%，2%）。

No new ILD events of any grade were adjudicated as drug-related since the previous analysis..

。。

In TROPION-Lung01, patient enrollment by tumour histology was balanced across treatment arms and consistent with real-world incidence with approximately 75% of enrolled patients having nonsquamous NSCLC.1,2 In both arms, 17% of patients had tumours expressing actionable genomic alterations, such as epidermal growth factor receptor (EGFR) mutations..

在TROPION-Lung01中，肿瘤组织学的患者登记在治疗组之间是平衡的，并且与现实世界的发病率一致，大约75%的登记患者患有非鳞状非小细胞肺癌。1,2在两组中，17%的患者的肿瘤表达可行的基因组改变，如表皮生长因子受体（EGFR）突变。。

This final analysis of OS builds on the positive progression-free survival (PFS) results presented at the 2023 European Society for Medical Oncology Congress, which showed datopotamab deruxtecan demonstrated a statistically significant improvement in PFS in the overall trial population and a clinically meaningful PFS benefit in patients with nonsquamous NSCLC.

这项对OS的最终分析建立在2023年欧洲肿瘤内科学会大会上提出的积极无进展生存期（PFS）结果的基础上，该结果显示达托巴单抗-德鲁替康在总体试验人群中显示出统计学上显着的PFS改善，并且在非鳞状非小细胞肺癌患者中具有临床意义的PFS益处。

The OS data have been shared with health authorities currently reviewing applications for this indication. .

操作系统数据已与目前正在审查该适应症应用程序的卫生当局共享。。

Summary of TROPION-Lung01 survival results

Overall trial population

总体试验人群

Datopotamab deruxtecan (n=299)

达托帕玛（n=299）

Docetaxel

多西紫杉醇

(n=305)

（n=305）

Median OS (95% CI)i

中位OS（95%置信区间）i

12.9 months (11.0-13.9)

12.9个月（11.0-13.9）

11.8 months (10.0-12.8)

11.8个月（10.0-12.8）

HR (95% CI)

人力资源（95%置信区间）

0.94 (0.78-1.14)

0.94 (0.78-1.14)

p-value

p值

0.530

0.530

Pre-specified boundary (2-sided)

预先指定的边界（双面）

0.045

0.045

Nonsquamous histology

非鳞状组织学

Datopotamab deruxtecan (n=234)

达托帕玛（n=234）

Docetaxel

多西紫杉醇

(n=234)

（n=234）

Median OS (95% CI)i

中位OS（95%置信区间）i

14.6 months (12.4-16.0)

14.6个月（12.4-16.0）

12.3 months (10.7-14.0)

12.3个月（10.7-14.0）

HR (95% CI)

人力资源（95%置信区间）

0.84 (0.68-1.05)

0.84 (0.68-1.05)

OS probability at 12 months (95% CI)

12个月时的OS概率（95%置信区间）

58.8% (52.0-64.9)

58.8% (52.0-64.9)

52.8% (45.9-59.2)

52.8% (45.9-59.2)

OS probability at 24 months (95% CI)

24个月时的OS概率（95%置信区间）

29.0% (22.8-35.5)

29.0% (22.8-35.5)

21.7% (16.0-28.0)

21.7% (16.0-28.0)

Nonsquamous histology – with actionable genomic alterations

非鳞状组织学-具有可行的基因组改变

Datopotamab deruxtecan (n=48)

达托帕玛（n=48）

Docetaxel

多西紫杉醇

(n=50)

（n=50）

Median OS (95% CI)i

中位OS（95%置信区间）i

15.6 months

15.6个月

9.8 months

9.8个月

HR (95% CI)

人力资源（95%置信区间）

0.65 (0.40-1.08)

0.65 (0.40-1.08)

Nonsquamous histology – without actionable genomic alterations

非鳞状组织学-没有可行的基因组改变

Datopotamab deruxtecan (n=186)

达托帕玛（n=186）

Docetaxel

多西紫杉醇

(n=184)

（n=184）

Median OS (95% CI)i

中位OS（95%置信区间）i

13.6 months

13.6个月

12.3 months

12.3个月

HR (95% CI)

人力资源（95%置信区间）

0.89 (0.70-1.13)

0.89 (0.70-1.13)

CI, confidence interval; HR, hazard ratio; OS, overall survival

CI，置信区间；HR，风险比；操作系统，总体生存

iMedian follow-up was 23.1 months for both the datopotamab deruxtecan and docetaxel arms

达托单抗-德鲁替康和多西他赛组的平均随访时间为23.1个月

Datopotamab deruxtecan plus Imfinzi and chemotherapy showed promising response rates in patients with early-stage resectable NSCLC

达托单抗-德鲁替康联合Imfinzi和化疗在早期可切除的非小细胞肺癌患者中显示出有希望的反应率

Results from the NeoCOAST-2 Phase II platform trial evaluating Imfinzi (durvalumab) in multiple novel combinations, before and after surgery, in patients with early-stage (Stage IIA-IIIB) resectable NSCLC were featured in a WCLC Presidential Symposium (PL02.07). Preliminary results from the trial arm testing neoadjuvant Imfinzi plus datopotamab deruxtecan and carboplatin demonstrated a pathological complete response (pCR) rate of 34.1% (95% CI 20.5-49.9) and a major pathological response (mPR) rate of 65.9% (95% CI 50.1-79.5).

WCLC总统研讨会（PL02.07）介绍了NeoCOAST-2 II期平台试验的结果，该试验评估了早期（IIA-IIIB期）可切除NSCLC患者手术前后多种新型组合的Imfinzi（durvalumab）。新辅助Imfinzi联合达托单抗-德鲁替康和卡铂试验组的初步结果显示，病理完全缓解率（pCR）为34.1%（95%CI 20.5-49.9），主要病理缓解率（mPR）为65.9%（95%CI 50.1-79.5）。

This was numerically higher than the response rates shown by other combination regimens tested, however, the trial was not powered to make direct statistical comparisons between arms..

这在数字上高于其他测试组合方案显示的反应率，但是，该试验无法对两组进行直接的统计比较。。

The safety profile of Imfinzi plus datopotamab deruxtecan and carboplatin was consistent with the known safety profiles of these agents. Surgical rates across arms were comparable and in line with those shown in recent Phase III trials. AstraZeneca and Daiichi Sankyo are evaluating datopotamab deruxtecan in combination with Imfinzi in multiple ongoing trials.  .

Imfinzi加达托单抗deruxtecan和卡铂的安全性与这些药物的已知安全性一致。双臂手术率相当，与最近的III期临床试验结果一致。阿斯利康（AstraZeneca）和第一三共（Daiichi Sankyo）正在多个正在进行的试验中评估达托巴单抗（datopotamab deruxtecan）联合Imfinzi。。

Also featured in a WCLC Presidential Symposium were results from an exploratory analysis of TROPION-Lung01 which showed TROP2 as measured by AstraZeneca’s proprietary computational pathology platform, quantitative continuous scoring (QCS), was predictive of clinical outcomes in patients with advanced or metastatic NSCLC treated with datopotamab deruxtecan..

在WCLC总统研讨会上还展示了对TROPION-Lung01进行探索性分析的结果，该分析显示，通过阿斯利康专有的计算病理学平台定量连续评分（QCS）测量的TROP2可预测用达托巴单抗治疗的晚期或转移性NSCLC患者的临床结果。。

Notes

注释

Advanced non-small cell lung cancer

晚期非小细胞肺癌

Nearly 2.5 million lung cancer cases were diagnosed globally in 2022.1 NSCLC is the most common type of lung cancer, accounting for about 80% of cases.2 Approximately 75% and 25% of NSCLC tumours are of nonsquamous or squamous histology, respectively.3 While immunotherapy and targeted therapies have improved outcomes in the 1st-line metastatic setting, most patients eventually experience disease progression and receive chemotherapy.4-6 For decades, chemotherapy has been the last treatment available for patients with advanced NSCLC, despite limited effectiveness and known side effects.4-6.

2022年，全球诊断出近250万例肺癌病例.1 NSCLC是最常见的肺癌类型，约占病例的80%.2约75%和25%的NSCLC肿瘤分别为非鳞状或鳞状组织学[3]。虽然免疫治疗和靶向治疗在一线转移治疗中改善了预后，但大多数患者最终会出现疾病进展并接受化疗[4-6]。几十年来，化疗一直是晚期NSCLC患者可用的最后一种治疗方法，尽管有效性和已知的副作用有限[4-6]。

TROP2 is a protein broadly expressed in the majority of NSCLC tumours.7 There is currently no TROP2-directed ADC approved for the treatment of lung cancer.8,9

TROPION-Lung01

TROPION-Lung01

TROPION-Lung01 is a global, randomised, multicentre, open-label Phase III trial evaluating the efficacy and safety of datopotamab deruxtecan (6.0mg/kg) versus docetaxel (75mg/m2) in adult patients with locally advanced or metastatic NSCLC with and without actionable genomic alterations who require systemic therapy following prior treatment.

TROPION-Lung01是一项全球性，随机，多中心，开放标签的III期临床试验，评估达托单抗-德鲁替康（6.0mg/kg）与多西紫杉醇（75mg/m2）在成人局部晚期或转移性NSCLC患者中的疗效和安全性，有无可行的基因组改变，需要在事先治疗后进行全身治疗。

Patients with actionable genomic alterations were previously treated with platinum-based chemotherapy and an approved targeted therapy. Patients without known actionable genomic alterations were previously treated, concurrently or sequentially, with platinum-based chemotherapy and a PD-1 or PD-L1 inhibitor..

具有可行基因组改变的患者先前接受过铂类化疗和经批准的靶向治疗。没有已知可行基因组改变的患者先前曾同时或顺序接受铂类化疗和PD-1或PD-L1抑制剂治疗。。

The dual primary endpoints of TROPION-Lung01 are PFS as assessed by blinded independent central review (BICR) and OS. Key secondary endpoints include investigator-assessed PFS, objective response rate (ORR), duration of response, time to response, disease control rate as assessed by both BICR and investigator, and safety..

通过盲法独立中央审查（BICR）和OS评估，TROPION-Lung01的双重主要终点是PFS。主要次要终点包括研究者评估的PFS，客观缓解率（ORR），缓解持续时间，缓解时间，BICR和研究者评估的疾病控制率以及安全性。。

TROPION-Lung01 enrolled approximately 600 patients in Asia, Europe, North America, Oceania and South America. For more information visit ClinicalTrials.gov.

TROPION-Lung01在亚洲，欧洲，北美，大洋洲和南美招募了大约600名患者。有关更多信息，请访问ClinicalTrials.gov。

NeoCOAST-2

新海岸-2

NeoCOAST-2 is a global, randomised, multicentre, open-label, multi-arm Phase II platform trial evaluating the efficacy and safety of Imfinzi in multiple novel combinations, before and after surgery, in patients with resectable, early-stage (Stage II-IIIB) NSCLC.

NeoCOAST-2是一项全球性，随机，多中心，开放标签，多臂II期平台试验，评估Imfinzi在手术前后多种新型组合中对可切除的早期（II-IIIB期）NSCLC患者的疗效和安全性。

The dual primary endpoints of NeoCOAST-2 are antitumour activity of neoadjuvant treatment assessed by pCR and the safety and tolerability of neoadjuvant and adjuvant treatment. Key secondary endpoints include event-free survival, disease-free survival and ORR as assessed by both RECIST version 1.1 and investigator, OS, tumour resection and mPR as defined by central blinded independent pathologist review..

NeoCOAST-2的双重主要终点是通过pCR评估的新辅助治疗的抗肿瘤活性以及新辅助和辅助治疗的安全性和耐受性。关键的次要终点包括RECIST 1.1版和中央盲法独立病理学家评论定义的研究者，OS，肿瘤切除和mPR评估的无事件生存率，无病生存率和ORR。。

NeoCOAST-2 will enrol approximately 490 patients in Asia, Europe and North America. For more information visit ClinicalTrials.gov.

NeoCOAST-2将在亚洲、欧洲和北美招收大约490名患者。有关更多信息，请访问ClinicalTrials.gov。

Datopotamab deruxtecan (Dato-DXd)

达托帕单抗（DXd数据）

Datopotamab deruxtecan (Dato-DXd) is an investigational TROP2-directed ADC. Designed using Daiichi Sankyo’s proprietary DXd ADC Technology, datopotamab deruxtecan is one of six DXd ADCs in the oncology pipeline of Daiichi Sankyo, and one of the most advanced programmes in AstraZeneca’s ADC scientific platform.

Datopotamab deruxtecan（Dato DXd）是一种研究性TROP2指导的ADC。datopotamab deruxtecan使用Daiichi Sankyo专有的DXd ADC技术设计，是Daiichi Sankyo肿瘤学管道中的六个DXd ADC之一，也是阿斯利康ADC科学平台中最先进的程序之一。

Datopotamab deruxtecan is comprised of a humanised anti-TROP2 IgG1 monoclonal antibody, developed in collaboration with Sapporo Medical University, attached to a number of topoisomerase I inhibitor payloads (an exatecan derivative, DXd) via tetrapeptide-based cleavable linkers..

Datopotamab deruxtecan由与札幌医科大学合作开发的人源化抗TROP2 IgG1单克隆抗体组成，通过基于四肽的可切割接头连接到许多拓扑异构酶I抑制剂有效载荷（exatecan衍生物DXd）。。

A comprehensive global clinical development programme is underway with more than 20 trials evaluating the efficacy and safety of datopotamab deruxtecan across multiple cancers, including NSCLC, triple-negative breast cancer and HR-positive, HER2-negative breast cancer. The programme includes seven Phase III trials in lung cancer and five Phase III trials in breast cancer evaluating datopotamab deruxtecan as a monotherapy and in combination with other anticancer treatments in various settings..

。该计划包括七项肺癌III期临床试验和五项乳腺癌III期临床试验，评估达托单抗-德鲁替康作为单一疗法以及在各种情况下与其他抗癌治疗相结合。。

Daiichi Sankyo collaboration

第一三共合作

AstraZeneca and Daiichi Sankyo entered into a global collaboration to jointly develop and commercialise Enhertu in March 2019 and datopotamab deruxtecan in July 2020, except in Japan where Daiichi Sankyo maintains exclusive rights for each ADC. Daiichi Sankyo is responsible for the manufacturing and supply of Enhertu and datopotamab deruxtecan..

阿斯利康（AstraZeneca）和第一三共（Daiichi Sankyo）于2019年3月达成全球合作，共同开发Enhertu，并于2020年7月将其商业化，但在日本，第一三共（Daiichi Sankyo）对每个ADC拥有专有权。Daiichi Sankyo负责Enhertu和datopotamab deruxtecan的制造和供应。。

AstraZeneca in lung cancer

阿斯利康治疗肺癌

AstraZeneca is working to bring patients with lung cancer closer to cure through the detection and treatment of early-stage disease, while also pushing the boundaries of science to improve outcomes in the resistant and advanced settings. By defining new therapeutic targets and investigating innovative approaches, the Company aims to match medicines to the patients who can benefit most..

阿斯利康正在努力通过早期疾病的检测和治疗，使肺癌患者更接近治愈，同时也推动了科学的界限，以改善耐药和晚期环境中的结果。通过定义新的治疗目标和研究创新方法，该公司旨在将药物与最能受益的患者相匹配。。

The Company’s comprehensive portfolio includes leading lung cancer medicines and the next wave of innovations, including Tagrisso (osimertinib) and Iressa (gefitinib); Imfinzi (durvalumab) and Imjudo (tremelimumab); Enhertu (trastuzumab deruxtecan) and datopotamab deruxtecan in collaboration with Daiichi Sankyo; Orpathys (savolitinib) in collaboration with HUTCHMED; as well as a pipeline of potential new medicines and combinations across diverse mechanisms of action..

该公司的综合投资组合包括领先的肺癌药物和下一波创新，包括Tagrisso（osimertinib）和Iressa（吉非替尼）；Imfinzi（durvalumab）和Imjudo（tremelimumab）；Enhertu（曲妥珠单抗deruxtecan）和达托帕单抗deruxtecan与Daiichi Sankyo合作；Orpathys（savolitinib）与HUTCHMED合作；以及跨越不同行动机制的潜在新药和组合渠道。。

AstraZeneca is a founding member of the Lung Ambition Alliance, a global coalition working to accelerate innovation and deliver meaningful improvements for people with lung cancer, including and beyond treatment.

阿斯利康是肺癌雄心联盟的创始成员，该联盟是一个全球联盟，致力于加速创新，为肺癌患者提供有意义的改善，包括治疗和其他治疗。

AstraZeneca in oncology

阿斯利康肿瘤学

AstraZeneca is leading a revolution in oncology with the ambition to provide cures for cancer in every form, following the science to understand cancer and all its complexities to discover, develop and deliver life-changing medicines to patients.

阿斯利康（AstraZeneca）正在领导一场肿瘤学革命，致力于为各种形式的癌症提供治疗，遵循科学理解癌症及其复杂性，发现、开发并向患者提供改变生命的药物。

The Company’s focus is on some of the most challenging cancers. It is through persistent innovation that AstraZeneca has built one of the most diverse portfolios and pipelines in the industry, with the potential to catalyse changes in the practice of medicine and transform the patient experience.

该公司专注于一些最具挑战性的癌症。正是通过不断的创新，阿斯利康建立了行业内最多样化的投资组合和渠道之一，有可能促进医学实践的变化并改变患者的体验。

AstraZeneca has the vision to redefine cancer care and, one day, eliminate cancer as a cause of death.

阿斯利康的愿景是重新定义癌症护理，并有一天消除癌症作为死亡原因。

AstraZeneca

阿斯利康

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.

阿斯利康（LSE/STO/Nasdaq:AZN）是一家全球科学领先的生物制药公司，专注于肿瘤学，罕见病和生物制药（包括心血管，肾脏和代谢以及呼吸和免疫学）处方药的发现，开发和商业化。

Based in Cambridge, UK, AstraZeneca’s innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on social media @AstraZeneca..

阿斯利康的创新药物总部位于英国剑桥，在125多个国家销售，全球数百万患者使用。请访问astrazeneca.com并在社交媒体@astrazeneca上关注该公司。。

Contacts

联系人

For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.

有关如何联系投资者关系团队的详细信息，请单击此处。有关媒体联系人，请单击此处。

References

参考文献

World Health Organization. Global Cancer Observatory: Lung. Available at:  https://gco.iarc.who.int/media/globocan/factsheets/cancers/15-trachea-bronchus-and-lung-fact-sheet.pdf. Accessed September 2024.

世界卫生组织。全球癌症观察站：肺。网址：https://gco.iarc.who.int/media/globocan/factsheets/cancers/15-trachea-bronchus-and-lung-fact-sheet.pdf.2024年9月访问。

Cancer.net. Lung Cancer – Non-Small Cell: Statistics. Available at: https://www.cancer.net/cancer-types/lung-cancer-non-small-cell/statistics#:~:text=NSCLC%20is%20the%20most%20common,be%20diagnosed%20with%20lung%20cancer. Accessed September 2024.

Cancer.net。肺癌-非小细胞：统计。网址：https://www.cancer.net/cancer-types/lung-cancer-non-small-cell/statistics#:~：text=NSCLC是最常见的，被诊断为肺癌。2024年9月访问。

National Cancer Institute. SEER Cancer Statistics Factsheets: Lung and Bronchus Cancer. Available at: https://seer.cancer.gov/archive/csr/1975_2017/results_merged/sect_15_lung_bronchus.pdf. Accessed September 2024.

国家癌症研究所。SEER癌症统计概况：肺癌和支气管癌。网址：https://seer.cancer.gov/archive/csr/1975_2017/results_merged/sect_15_lung_bronchus.pdf.2024年9月访问。

Chen R, et al. Emerging therapeutic agents for advanced non-small cell lung cancer. J Hematol Oncol. 2020;13(1):58.

陈R等。晚期非小细胞肺癌的新兴治疗药物。J Hematol Oncol。2020年；13（1）：58。

Majeed U, et al. Targeted therapy in advanced non-small cell lung cancer: current advances and future trends. J Hematol Oncol. 2021;14(1):108.

Majeed U等人。晚期非小细胞肺癌的靶向治疗：当前进展和未来趋势。J Hematol Oncol。；14（1）：108。

Pircher, A, et al. Docetaxel in the Treatment of Non-small Cell Lung Cancer (NSCLC) – An Observational Study Focusing on Symptom Improvement. Anticancer Research. 2013;33(9):3831-3836.

Pircher，A等人。多西紫杉醇治疗非小细胞肺癌（NSCLC）——一项关注症状改善的观察性研究。抗癌研究。2013年；33（9）：3831-3836。

Mito R, et al. Clinical impact of TROP2 in non‐small lung cancers and its correlation with abnormal p53 nuclear accumulation. Pathol Int. 2020;70(5):287-294.

Mito R等人。TROP2在非小细胞肺癌中的临床影响及其与异常p53核积聚的相关性。Pathol Int.2020；70（5）：287-294。

Rodríguez-Abreau D, et al. Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189. Ann Onc. 2021 Jul;32(7): 881-895.

Rodríguez-Abreau D等人。培美曲塞加铂联合或不联合pembrolizumab治疗先前未经治疗的转移性非鳞状细胞癌患者：KEYNOTE-189的方案指定最终分析。Ann Onc。2021年7月；32（7）：881-895。

American Cancer Society. Targeted Drug Therapy for Non-Small Cell Lung Cancer. Available at: https://www.cancer.org/cancer/types/lung-cancer/treating-non-small-cell/targeted-therapies.html. Accessed September 2024.

美国癌症协会。非小细胞肺癌的靶向药物治疗。网址：https://www.cancer.org/cancer/types/lung-cancer/treating-non-small-cell/targeted-therapies.html.2024年9月访问。